linkedin

IR Notice

Notice

CEO IR Newletter


 

??%202.png
 

Dear Investors, This is John Rim, CEO and President of Samsung Biologics.

I want to take a moment to thank you all for your unwavering support during what has been a breakthrough year of growth and opportunity here at Samsung Biologics. Today, our company announced the buyout of Biogen's stake in Samsung Bioepis joint venture of 10,341,852 shares for USD 2.3 billion. This decision lays a strong foundation for Samsung Biologics to further grow as a global biopharmaceutical company as part of our vision for 2030. This is a bold investment, the largest since Samsung Electronics' acquisition of Harman in 2016, with the strategic aim to establish biotechnology as the next growth engine with greater opportunities ahead. Samsung Bioepis has built a diversified business portfolio, launching biosimilars for autoimmune disease and oncology upon its founding in 2012 as a joint venture with Biogen. Samsung Bioepis has successfully launched five biosimilars in the global market, three in autoimmune and two in oncology, and with five additional products in its pipeline. Samsung Bioepis has recorded its first turnaround of surplus in operating profit in 2019 which is an astounding achievement within 8 years since its establishment. The acquisition is expected to improve the autonomy and agility in Samsung Bioepis' decisionmaking, further boosting its growth outlook in the future. The full buyout of Biogen's stake will accelerate our biosimilar development capabilities and future performance in novel drug development, and the deal will further deliver Samsung Bioepis' sales growth and operating margin improvements with streamlined operational efficiencies, budget surplus, and cash flow generation. We will continue to be in close communication with Biogen to work collaboratively for our future growth together. For the purchase of Bioepsis shares and to fund the company's strategic growth plans, we have decided to raise the capital of KRW 3 trillion by issuing new shares. By expanding our portfolio, we will evolve to become a global biopharmaceutical company as the next growth engine with great responsibilities to better serve our clients, shareholders, and ultimately society.

Our company continues to hold the world's largest biomanufacturing capacity since 2019 and is advancing forward through active investment with unparalleled innovation. We are currently building Plant 4 and will begin construction of Plant 5 this year, which will offer multi-modal product services, venturing into expanding business portfolio for cell and gene therapies and next-gen vaccines utilizing mRNA, PDNA and viral vectors, all at a single site, in addition to mRNA DP and DS manufacturing. We are also in the process of securing additional land of 350,000m2 for Bio Campus II, which will be 30% larger than the size of the current site. At a time of great momentum for change and advancement, your continued support is indispensable. We ask for your continued trust and support for the success of Samsung Biologics. Thank you.

Sincerely, 2022.1.28 CEO and President of Samsung Biologics John Rim

 

??%202.png
 

Dear Investors, This is John Rim, CEO and President of Samsung Biologics.

I want to take a moment to thank you all for your unwavering support during what has been a breakthrough year of growth and opportunity here at Samsung Biologics. Today, our company announced the buyout of Biogen's stake in Samsung Bioepis joint venture of 10,341,852 shares for USD 2.3 billion. This decision lays a strong foundation for Samsung Biologics to further grow as a global biopharmaceutical company as part of our vision for 2030. This is a bold investment, the largest since Samsung Electronics' acquisition of Harman in 2016, with the strategic aim to establish biotechnology as the next growth engine with greater opportunities ahead. Samsung Bioepis has built a diversified business portfolio, launching biosimilars for autoimmune disease and oncology upon its founding in 2012 as a joint venture with Biogen. Samsung Bioepis has successfully launched five biosimilars in the global market, three in autoimmune and two in oncology, and with five additional products in its pipeline. Samsung Bioepis has recorded its first turnaround of surplus in operating profit in 2019 which is an astounding achievement within 8 years since its establishment. The acquisition is expected to improve the autonomy and agility in Samsung Bioepis' decisionmaking, further boosting its growth outlook in the future. The full buyout of Biogen's stake will accelerate our biosimilar development capabilities and future performance in novel drug development, and the deal will further deliver Samsung Bioepis' sales growth and operating margin improvements with streamlined operational efficiencies, budget surplus, and cash flow generation. We will continue to be in close communication with Biogen to work collaboratively for our future growth together. For the purchase of Bioepsis shares and to fund the company's strategic growth plans, we have decided to raise the capital of KRW 3 trillion by issuing new shares. By expanding our portfolio, we will evolve to become a global biopharmaceutical company as the next growth engine with great responsibilities to better serve our clients, shareholders, and ultimately society.

Our company continues to hold the world's largest biomanufacturing capacity since 2019 and is advancing forward through active investment with unparalleled innovation. We are currently building Plant 4 and will begin construction of Plant 5 this year, which will offer multi-modal product services, venturing into expanding business portfolio for cell and gene therapies and next-gen vaccines utilizing mRNA, PDNA and viral vectors, all at a single site, in addition to mRNA DP and DS manufacturing. We are also in the process of securing additional land of 350,000m2 for Bio Campus II, which will be 30% larger than the size of the current site. At a time of great momentum for change and advancement, your continued support is indispensable. We ask for your continued trust and support for the success of Samsung Biologics. Thank you.

Sincerely, 2022.1.28 CEO and President of Samsung Biologics John Rim

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved